Healthcare entity
Every one of those 1 sits in a single category, medical-devices. Sean Menargas is most often covered alongside Charles Schwab, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 3.3 for the same window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, medical-devices. Sean Menargas is most often covered alongside Charles Schwab, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 3.3 for the same window. Their average consequence score of 7 runs above the beat's 6.6 for that window. Sean Menargas appears in 1 tracked Healthcare story from March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sean Menargas. Shared-story counts are live from our verified record — not editorial picks.
MaxCyte reported a 15% revenue decline for 2025, driven by the loss of six clinical programs and reduced spending from its largest customer. Despite these headwinds, the company expanded its installed base to 857 units and significantly improved gross margins through aggressive cost-cutting measures.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
Sean Menargas is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
